GB201706406D0 - Method of treatment - Google Patents

Method of treatment

Info

Publication number
GB201706406D0
GB201706406D0 GBGB1706406.4A GB201706406A GB201706406D0 GB 201706406 D0 GB201706406 D0 GB 201706406D0 GB 201706406 A GB201706406 A GB 201706406A GB 201706406 D0 GB201706406 D0 GB 201706406D0
Authority
GB
United Kingdom
Prior art keywords
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1706406.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Volution Immuno Pharmaceuticals SA
Original Assignee
Volution Immuno Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volution Immuno Pharmaceuticals SA filed Critical Volution Immuno Pharmaceuticals SA
Priority to GBGB1706406.4A priority Critical patent/GB201706406D0/en
Publication of GB201706406D0 publication Critical patent/GB201706406D0/en
Priority to IL269895A priority patent/IL269895B2/en
Priority to DK18726731.5T priority patent/DK3612208T5/da
Priority to IL269856A priority patent/IL269856B2/en
Priority to PCT/EP2018/060240 priority patent/WO2018193121A1/en
Priority to CA3060331A priority patent/CA3060331A1/en
Priority to PCT/EP2018/060241 priority patent/WO2018193122A1/en
Priority to US16/603,357 priority patent/US11214602B2/en
Priority to AU2018253960A priority patent/AU2018253960A1/en
Priority to PL18726731.5T priority patent/PL3612208T3/pl
Priority to EP23166056.4A priority patent/EP4275696A1/en
Priority to CN201880041705.4A priority patent/CN110831617A/zh
Priority to AU2018253961A priority patent/AU2018253961B2/en
Priority to EP18726731.5A priority patent/EP3612208B1/en
Priority to PL18719169.7T priority patent/PL3612207T3/pl
Priority to JP2019556794A priority patent/JP7209637B2/ja
Priority to AU2018253962A priority patent/AU2018253962B2/en
Priority to KR1020197031710A priority patent/KR102630702B1/ko
Priority to CA3059657A priority patent/CA3059657A1/en
Priority to KR1020197031685A priority patent/KR20190138650A/ko
Priority to EP18719168.9A priority patent/EP3612206A1/en
Priority to PCT/EP2018/060239 priority patent/WO2018193120A1/en
Priority to JP2019556928A priority patent/JP7183180B2/ja
Priority to JP2019556909A priority patent/JP7153669B2/ja
Priority to CN201880040770.5A priority patent/CN110799207B/zh
Priority to KR1020197031711A priority patent/KR102656199B1/ko
Priority to US16/603,352 priority patent/US11730792B2/en
Priority to CA3060336A priority patent/CA3060336A1/en
Priority to CN201880041710.5A priority patent/CN110896606B/zh
Priority to EP18719169.7A priority patent/EP3612207B1/en
Priority to US16/603,354 priority patent/US20210113658A1/en
Priority to ES18726731T priority patent/ES2945433T3/es
Priority to ES18719169T priority patent/ES2980279T3/es
Priority to US17/529,534 priority patent/US20230002456A1/en
Priority to JP2022159216A priority patent/JP2022188170A/ja
Priority to JP2023001554A priority patent/JP7600278B2/ja
Priority to US18/332,191 priority patent/US20240009270A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43527—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
GBGB1706406.4A 2017-04-21 2017-04-21 Method of treatment Ceased GB201706406D0 (en)

Priority Applications (37)

Application Number Priority Date Filing Date Title
GBGB1706406.4A GB201706406D0 (en) 2017-04-21 2017-04-21 Method of treatment
ES18719169T ES2980279T3 (es) 2017-04-21 2018-04-20 Variantes de Coversin que carecen de unión a C5
CA3059657A CA3059657A1 (en) 2017-04-21 2018-04-20 Coversin for the treatment of autoimmune blistering diseases
KR1020197031685A KR20190138650A (ko) 2017-04-21 2018-04-20 반흔성 안구 염증성 장애의 치료를 위한 코버신
IL269856A IL269856B2 (en) 2017-04-21 2018-04-20 Coversin variants lack C5 linkers
PCT/EP2018/060240 WO2018193121A1 (en) 2017-04-21 2018-04-20 Coversin variants lacking c5 binding
CA3060331A CA3060331A1 (en) 2017-04-21 2018-04-20 Coversin for the treatment of cicatrising eye inflammatory disorders
PCT/EP2018/060239 WO2018193120A1 (en) 2017-04-21 2018-04-20 Coversin for the treatment of cicatrising eye inflammatory disorders
US16/603,357 US11214602B2 (en) 2017-04-21 2018-04-20 Coversin variants lacking C5 binding
AU2018253960A AU2018253960A1 (en) 2017-04-21 2018-04-20 Coversin for the treatment of cicatrising eye inflammatory disorders
PL18726731.5T PL3612208T3 (pl) 2017-04-21 2018-04-20 Coversin do leczenia autoimmunologicznych chorób pęcherzowych
EP23166056.4A EP4275696A1 (en) 2017-04-21 2018-04-20 Coversin for the treatment of autoimmune blistering diseases
CN201880041705.4A CN110831617A (zh) 2017-04-21 2018-04-20 用于治疗瘢痕性眼部发炎性病症的Coversin
AU2018253961A AU2018253961B2 (en) 2017-04-21 2018-04-20 Coversin variants lacking C5 binding
EP18726731.5A EP3612208B1 (en) 2017-04-21 2018-04-20 Coversin for the treatment of autoimmune blistering diseases
PL18719169.7T PL3612207T3 (pl) 2017-04-21 2018-04-20 Warianty coversin niewykazujące wiązania c5
JP2019556794A JP7209637B2 (ja) 2017-04-21 2018-04-20 自己免疫性水疱症の治療のためのコバーシン
AU2018253962A AU2018253962B2 (en) 2017-04-21 2018-04-20 Coversin for the treatment of autoimmune blistering diseases
KR1020197031710A KR102630702B1 (ko) 2017-04-21 2018-04-20 C5 결합이 없는 코버신(coversin) 변이체
IL269895A IL269895B2 (en) 2017-04-21 2018-04-20 Coversin for the treatment of autoimmune blistering diseases
EP18719168.9A EP3612206A1 (en) 2017-04-21 2018-04-20 Coversin for the treatment of cicatrising eye inflammatory disorders
DK18726731.5T DK3612208T5 (da) 2017-04-21 2018-04-20 Coversin til behandlingen af autoimmune sygdomme med blisterdannelse
PCT/EP2018/060241 WO2018193122A1 (en) 2017-04-21 2018-04-20 Coversin for the treatment of autoimmune blistering diseases
JP2019556928A JP7183180B2 (ja) 2017-04-21 2018-04-20 Ｃ５結合性を欠失したコバーシンバリアント
JP2019556909A JP7153669B2 (ja) 2017-04-21 2018-04-20 瘢痕性眼炎症障害の治療のためのコバーシン
CN201880040770.5A CN110799207B (zh) 2017-04-21 2018-04-20 缺少C5结合的Coversin变体
KR1020197031711A KR102656199B1 (ko) 2017-04-21 2018-04-20 자가면역 수포 질환의 치료를 위한 코버신
US16/603,352 US11730792B2 (en) 2017-04-21 2018-04-20 Coversin (OmCI) for the treatment of autoimmune blistering diseases: bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA)
CA3060336A CA3060336A1 (en) 2017-04-21 2018-04-20 Coversin variants lacking c5 binding
CN201880041710.5A CN110896606B (zh) 2017-04-21 2018-04-20 用于治疗自身免疫性水疱病的coversin
EP18719169.7A EP3612207B1 (en) 2017-04-21 2018-04-20 Coversin variants lacking c5 binding
US16/603,354 US20210113658A1 (en) 2017-04-21 2018-04-20 Coversin for the treatment of cicatrising eye inflammatory disorders
ES18726731T ES2945433T3 (es) 2017-04-21 2018-04-20 Coversina para el tratamiento de enfermedades ampollares autoinmunes
US17/529,534 US20230002456A1 (en) 2017-04-21 2021-11-18 Coversin Variants Lacking C5 Binding
JP2022159216A JP2022188170A (ja) 2017-04-21 2022-10-03 瘢痕性眼炎症障害の治療のためのコバーシン
JP2023001554A JP7600278B2 (ja) 2017-04-21 2023-01-10 自己免疫性水疱症の治療のためのコバーシン
US18/332,191 US20240009270A1 (en) 2017-04-21 2023-06-09 Coversin for the treatment of autoimmune blistering diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1706406.4A GB201706406D0 (en) 2017-04-21 2017-04-21 Method of treatment

Publications (1)

Publication Number Publication Date
GB201706406D0 true GB201706406D0 (en) 2017-06-07

Family

ID=58795719

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1706406.4A Ceased GB201706406D0 (en) 2017-04-21 2017-04-21 Method of treatment

Country Status (12)

Country Link
US (2) US11214602B2 (enExample)
EP (1) EP3612207B1 (enExample)
JP (1) JP7183180B2 (enExample)
KR (1) KR102630702B1 (enExample)
CN (1) CN110799207B (enExample)
AU (1) AU2018253961B2 (enExample)
CA (1) CA3060336A1 (enExample)
ES (1) ES2980279T3 (enExample)
GB (1) GB201706406D0 (enExample)
IL (1) IL269856B2 (enExample)
PL (1) PL3612207T3 (enExample)
WO (1) WO2018193121A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3612206A1 (en) * 2017-04-21 2020-02-26 Volution Immuno Pharmaceuticals SA Coversin for the treatment of cicatrising eye inflammatory disorders
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
DK3612208T5 (da) * 2017-04-21 2024-09-02 Volution Immuno Pharmaceuticals Sa Coversin til behandlingen af autoimmune sygdomme med blisterdannelse
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
AU2019468121A1 (en) 2019-09-27 2022-05-12 Volution Immuno Pharmaceuticals Sa Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA)
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001241156A1 (en) * 2000-03-21 2001-10-03 Yamanouchi Pharmaceutical Co..Ltd. Novel leukotriene b4 receptor
EP1575496A4 (en) * 2002-04-05 2008-01-23 Univ Utah Res Found COLON TUMOR SPECIFIC BINDING PEPTIDES
MXPA05012880A (es) 2003-06-02 2006-02-22 Evolutec Ltd Inhibidores de complemento.
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
EA200901211A1 (ru) 2007-03-22 2010-04-30 Новартис Аг Антигены белка с5 и их применение
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
GB0906779D0 (en) * 2009-04-20 2009-06-03 Natural Environment Res Council Composition
ES3044832T3 (en) 2011-06-22 2025-11-27 Apellis Pharmaceuticals Inc Methods of treating chronic disorders with complement inhibitors
GB201410031D0 (en) 2014-06-05 2014-07-16 Isis Innovation Polypeptides and uses thereof
WO2016198133A1 (en) 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
EP3612206A1 (en) 2017-04-21 2020-02-26 Volution Immuno Pharmaceuticals SA Coversin for the treatment of cicatrising eye inflammatory disorders
DK3612208T5 (da) 2017-04-21 2024-09-02 Volution Immuno Pharmaceuticals Sa Coversin til behandlingen af autoimmune sygdomme med blisterdannelse

Also Published As

Publication number Publication date
KR102630702B1 (ko) 2024-01-29
JP7183180B2 (ja) 2022-12-05
CN110799207B (zh) 2024-05-03
WO2018193121A1 (en) 2018-10-25
AU2018253961B2 (en) 2022-06-02
JP2020517260A (ja) 2020-06-18
CA3060336A1 (en) 2018-10-25
US11214602B2 (en) 2022-01-04
IL269856B2 (en) 2024-09-01
CN110799207A (zh) 2020-02-14
PL3612207T3 (pl) 2024-09-23
US20230002456A1 (en) 2023-01-05
KR20190141163A (ko) 2019-12-23
EP3612207C0 (en) 2024-04-10
EP3612207A1 (en) 2020-02-26
US20200385434A1 (en) 2020-12-10
AU2018253961A1 (en) 2019-10-31
IL269856A (en) 2019-11-28
IL269856B1 (en) 2024-05-01
ES2980279T3 (es) 2024-09-30
EP3612207B1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
ZA201706059B (en) Method of treatment with tradipitant
GB2567616B (en) Treatment method
GB201410116D0 (en) Method of treatment
EP3684342C0 (en) TREATMENT PROCEDURES
GB201706406D0 (en) Method of treatment
GB201815588D0 (en) Method of treatment
ZA201705877B (en) Method of treating diseases
ZA201908539B (en) Method of treatment of cancer
SG11202001806TA (en) Treatment method
IL253028A0 (en) treatment method
GB2571601B (en) Treatment method
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
GB201602802D0 (en) Method of treatment
SG11202105877YA (en) Method of treatment
GB201512139D0 (en) Methods of treatment
GB201720439D0 (en) Method of treatment
GB201718589D0 (en) Method of treatment
GB201709554D0 (en) Method of treatment
GB201706642D0 (en) Method of treatment
GB201706452D0 (en) Method of treatment
GB201706398D0 (en) Method of treatment
GB201706404D0 (en) Method of treatment
GB201820236D0 (en) Method of treatment
GB201820157D0 (en) Method of treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)